Wall Street Zen Downgrades Lifevantage (NASDAQ:LFVN) to Buy

Lifevantage (NASDAQ:LFVN) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

Lifevantage Price Performance

Lifevantage stock opened at $12.11 on Friday. Lifevantage has a 12-month low of $8.17 and a 12-month high of $27.38. The stock has a market capitalization of $152.46 million, a P/E ratio of 16.36 and a beta of 0.39. The firm’s 50-day moving average is $13.14 and its two-hundred day moving average is $13.67.

Lifevantage (NASDAQ:LFVN) last released its quarterly earnings results on Thursday, September 4th. The company reported $0.17 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.17. Lifevantage had a net margin of 4.29% and a return on equity of 34.88%. The company had revenue of $55.11 million for the quarter, compared to analysts’ expectations of $57.93 million. During the same period last year, the company earned $0.14 EPS. Lifevantage has set its FY 2026 guidance at 1.000-1.15 EPS.

Insider Buying and Selling

In related news, CFO Carl Aure sold 2,746 shares of the firm’s stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $13.39, for a total value of $36,768.94. Following the transaction, the chief financial officer owned 133,303 shares in the company, valued at approximately $1,784,927.17. This trade represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 20.65% of the company’s stock.

Institutional Trading of Lifevantage

A number of hedge funds have recently made changes to their positions in the company. Jane Street Group LLC increased its stake in shares of Lifevantage by 5.4% in the first quarter. Jane Street Group LLC now owns 36,567 shares of the company’s stock worth $533,000 after buying an additional 1,877 shares during the last quarter. Farther Finance Advisors LLC acquired a new stake in Lifevantage in the second quarter worth about $25,000. Cetera Investment Advisers lifted its holdings in Lifevantage by 10.8% in the 2nd quarter. Cetera Investment Advisers now owns 20,098 shares of the company’s stock valued at $263,000 after acquiring an additional 1,954 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in Lifevantage in the 2nd quarter valued at about $31,000. Finally, Cambridge Investment Research Advisors Inc. raised its holdings in Lifevantage by 23.2% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 12,867 shares of the company’s stock worth $188,000 after buying an additional 2,421 shares during the period. Hedge funds and other institutional investors own 35.32% of the company’s stock.

Lifevantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.